# A Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC).

> **NCT01266499** · NA · COMPLETED · sponsor: **Rambam Health Care Campus** · enrollment: 200 (actual)

## Conditions studied

- Klebsiella Pneumoniae Carbapenemase Resistant Associated Bacteremia or Pneumonia

## Interventions

- **DRUG:** Colistin (Polymyxin E) 100mg x 4/d
- **DRUG:** both medications
- **DRUG:** will not receive PO treatment
- **DRUG:** PO Garamycin 80mg x 4/d

## Key facts

- **NCT ID:** NCT01266499
- **Lead sponsor:** Rambam Health Care Campus
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2011-01
- **Final completion:** 2012-01
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2017-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01266499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01266499, "A Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01266499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*